Carmofur (HCFU)
Mifurol · Antimetabolite (oral 5-FU prodrug)
Lipophilic oral 5-FU prodrug (Japan); class-level renal risk; hallmark toxicity is leukoencephalopathy not nephropathy.
Antimetabolite (oral 5-FU prodrug)
UFT · UFT
Antimetabolite (oral 5-FU prodrug) · approved 1984 · 4 citations
Describes how this page is sourced, not how dangerous the drug is. Thinly sourced means fewer of the sourcing signals are met — not that the agent is kidney-safe. A rule-based summary, not a formal certainty appraisal.
Oral 5-FU prodrug (tegafur + uracil); kidney-sparing as a class, with rare fluoropyrimidine-associated thrombotic microangiopathy.
Atlas fields gathered in one place, each linked to the section with its full text and sources. Educational, not medical advice.
Signature lesion
Direct renal injury from UFT is rare and largely class-level. Fluoropyrimidine-associated thrombotic microangiopathy / hemolytic-uremic syndrome is a rare, mostly case-report-level event, frequently in combination regimens (e.g., with mitomycin C). No reliable drug-specific incidence rate is established.Source: Anai et al., case report 1990 (HUS with UFT + mitomycin C); not quantified
TMA/HUS after weeks to months of cumulative exposure.
Distilled from: “Variable; TMA/HUS typically emerges after weeks to months of cumulative exposure.”
This agent's kidney lesions ordered by prominence — the #1 signature lesion first, then secondary and rare patterns. Cited incidence is shown where a citable figure exists; otherwise the tier stands qualitatively.
Endothelial injury with microvascular thrombi, hemolysis and thrombocytopenia — gemcitabine, mitomycin C, anti-VEGF.
Renal electrolyte derangement — magnesium/potassium/calcium wasting (cisplatin, anti-EGFR antibodies) or retention (FGFR-inhibitor hyperphosphatemia, tumor-lysis hyperkalemia/hyperphosphatemia).
Renal hypoperfusion from capillary leak and cytokine storm — IL-2 and CAR-T cytokine release syndrome.
Tap a signature to trace where it strikes the nephron.
Thrombotic Microangiopathy strikes: Glomerulus, Vasculature / Endothelium.
Thrombotic Microangiopathy
Endothelial injury with microvascular thrombi, hemolysis and thrombocytopenia — gemcitabine, mitomycin C, anti-VEGF.
Oral combination of tegafur (a prodrug bioactivated to 5-fluorouracil) and uracil in a 1:4 molar ratio. Uracil competitively inhibits dihydropyrimidine dehydrogenase, raising and sustaining intratumoral 5-FU concentrations. 5-FU's active metabolites (FdUMP, FUTP) inhibit thymidylate synthase and are incorporated into RNA/DNA, impairing nucleotide synthesis.
Class-level context for the major non-renal toxicities of the Antimetabolite (oral 5-FU prodrug) class.
Gastrointestinal
Diarrhea, colitis, mucositis, perforation
Hepatic / Liver
Transaminitis, hepatitis, VOD/SOS
Hematologic
Cytopenias, thrombosis, TMA
Pulmonary
Pneumonitis, ILD, effusions, hypertension
3 primary references — trials, cohorts, mechanism, and reviews. Single-patient case reports are listed separately below, graded by strength. Citation metadata via PubMed / NLM.
Primary (non–case-report) references per year — a proxy for how actively the agent's renal literature is accruing. Recent years are highlighted. Reflects curation depth, not a systematic bibliometric count.
Single-patient and small-series reports, graded by evidentiary strength — A Strong (biopsy-proven plus a series and/or positive rechallenge), B Moderate, and C Limited (a single clinically-diagnosed case). Strongest first. Grades are inferred automatically from each report's abstract and journal — a heuristic ranking aid, not a formal quality appraisal.
Everything below is FAERS — adverse events someone chose to report, about 239 of them for this agent. Nobody counts the patients who were fine, so none of these numbers is an incidence, a risk, or a rate: they describe what gets reported, shaped by a drug's fame, its indication, and who was watching. How these numbers work.
Only significant signals appear (95% CI lower bound above 1) — a phenotype missing here was tested and did not reach significance, except Prerenal / Hemodynamic AKI, Pseudo-AKI, Renal Cysts, Chronic Interstitial Nephropathy — outside the clinician-reviewed MedDRA term map, never queried — and ATN and AIN, queried but biopsy-bound: real cases are filed as generic “acute kidney injury”, so their absence is not a negative. As of 2026-11-15.
What reporting says about this profile's documented lesions
Counted by the report's active-substance field, which FAERS fills almost only on reports received from 2013 on, so these figures describe reports since then, not the agent's whole history.
Reported with a death outcome
49 of 239 reports
Reported with hospitalization
76 of 239 reports
Reports per year
Reports received per year, 2015–2026 · most recent year is partial · 36 of the 239 reports predate 2015 and are not drawn.
Bars rank systems by summed reaction-term mentions (a report counts once per term it names) — an ordinal “more vs less reported” cue, not a tally of distinct reports. Renal & urinary first. As of 2026-11-15.
Each recommendation below is this atlas's faithful summary of the source, not a quotation from it — follow the PubMed link for the wording the society published. Summaries may be superseded; consult the current full text and individualize to the patient.
General onco-nephrology references
Where Tegafur-uracil (UFT) sits in nephrotoxicity space — each dot is an anti-cancer agent, positioned so neighbors share a kidney-injury phenotype. Its 6 closest are filled and lead to a numbered marker, matching the numbered cards below.
Mifurol · Antimetabolite (oral 5-FU prodrug)
Lipophilic oral 5-FU prodrug (Japan); class-level renal risk; hallmark toxicity is leukoencephalopathy not nephropathy.
Furtulon · Antimetabolite (oral 5-FU prodrug)
5'-DFUR prodrug; class-level TMA risk plus a real renal-clearance component warranting caution in renal impairment.
Rasonque · RAS(ON) multi-selective inhibitor
2026 first RAS(ON) inhibitor (mutant + wild-type RAS) for pretreated metastatic pancreatic cancer; creatinine rose in 24% vs 9% on chemotherapy beside 67% diarrhea, and the label names one renal-limited TMA.
Lumoxiti · Immunotoxin (anti-CD22 PE38)
Boxed warning for capillary-leak syndrome and hemolytic-uremic syndrome / TMA.
Jakafi · JAK1/2 inhibitor
Tumor lysis in myelofibrosis; renally adjusted.
Dacogen · Hypomethylating agent
Tumor lysis in MDS/AML.
Nearest agents by kidney-injury phenotype (shared injuries, nephron target, severity, class) — a similarity approximation, not a claim of shared drug identity or mechanism.
Same-class agents ordered by their documented kidney-injury profile — atlas severity, an acute-kidney-injury FAERS signal, and how many injury types each is documented to cause. Agents nearer the top carry the lighter documented renal profile. Agents sharing a number are tied on all three. An agent marked FAERS n/a has too few reports to test, so its place rests on severity and injury breadth alone.
A comparison of documented kidney-injury data within one drug class — not a substitution recommendation. Efficacy, indication, and non-renal toxicity differ between these agents and are out of scope here. Educational only, not medical advice.